Literature DB >> 32667979

Implications of Efavirenz Pharmacogenetics When Switching From Efavirenz- to Dolutegravir-containing Antiretroviral Regimens.

David W Haas1,2, Edward P Acosta3.   

Abstract

Many patients switch from efavirenz- to dolutegravir-based regimens. In a phase 1 dolutegravir-efavirenz interaction study, mean dolutegravir minimum concentration decreased by 60% and 85% among CYP2B6 normal and slow/intermediate metabolizers, respectively. Mean efavirenz half-life was 2.7 times greater in slow vs normal metabolizers. Slow metabolizers will experience more prolonged subtherapeutic dolutegravir concentrations.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  dolutegravir; efavirenz; pharmacogenetics

Year:  2021        PMID： 32667979      PMCID： PMC8130017          DOI： 10.1093/cid/ciaa975

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  9 in total

1.  Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.

Authors:  Benoît Trottier; Jordan E Lake; Ken Logue; Cynthia Brinson; Lizette Santiago; Clare Brennan; Justin A Koteff; Brian Wynne; Judy Hopking; Catherine Granier; Michael Aboud
Journal:  Antivir Ther       Date:  2017-04-12

2.  Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial.

Authors:  Jan van Lunzen; Franco Maggiolo; José R Arribas; Aza Rakhmanova; Patrick Yeni; Benjamin Young; Jürgen K Rockstroh; Steve Almond; Ivy Song; Cindy Brothers; Sherene Min
Journal:  Lancet Infect Dis       Date:  2011-10-20       Impact factor: 25.071

3.  Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.

Authors:  Michael Aboud; Richard Kaplan; Johannes Lombaard; Fujie Zhang; José A Hidalgo; Elmira Mamedova; Marcelo H Losso; Ploenchan Chetchotisakd; Carlos Brites; Jörg Sievers; Dannae Brown; Judy Hopking; Mark Underwood; Maria Claudia Nascimento; Yogesh Punekar; Martin Gartland; Kimberly Smith
Journal:  Lancet Infect Dis       Date:  2019-02-04       Impact factor: 25.071

4.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Authors:  Zeruesenay Desta; Roseann S Gammal; Li Gong; Michelle Whirl-Carrillo; Aditya H Gaur; Chonlaphat Sukasem; Jennifer Hockings; Alan Myers; Marelize Swart; Rachel F Tyndale; Collen Masimirembwa; Otito F Iwuchukwu; Sanika Chirwa; Jeffrey Lennox; Andrea Gaedigk; Teri E Klein; David W Haas
Journal:  Clin Pharmacol Ther       Date:  2019-07-05       Impact factor: 6.875

5.  Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.

Authors:  Jose L Blanco; Jhon Rojas; Roger Paredes; Eugenia Negredo; Josep Mallolas; Maria Casadella; Bonaventura Clotet; Jose M Gatell; Elisa de Lazzari; Esteban Martinez
Journal:  J Antimicrob Chemother       Date:  2018-07-01       Impact factor: 5.790

6.  Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.

Authors:  Ingeborg Wijting; Casper Rokx; Charles Boucher; Jeroen van Kampen; Suzan Pas; Theodora de Vries-Sluijs; Carolina Schurink; Hannelore Bax; Maarten Derksen; Eleni-Rosalina Andrinopoulou; Marchina van der Ende; Eric van Gorp; Jan Nouwen; Annelies Verbon; Wouter Bierman; Bart Rijnders
Journal:  Lancet HIV       Date:  2017-10-26       Impact factor: 12.767

7.  Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants.

Authors:  Emily R Holzinger; Benjamin Grady; Marylyn D Ritchie; Heather J Ribaudo; Edward P Acosta; Gene D Morse; Roy M Gulick; Gregory K Robbins; David B Clifford; Eric S Daar; Paul McLaren; David W Haas
Journal:  Pharmacogenet Genomics       Date:  2012-12       Impact factor: 2.089

8.  Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir.

Authors:  Ivy Song; Julie Borland; Shuguang Chen; Phyllis Guta; Yu Lou; David Wilfret; Toshihiro Wajima; Paul Savina; Amanda Peppercorn; Stephen Castellino; David Wagner; Louise Hosking; Michael Mosteller; Justin P Rubio; Stephen C Piscitelli
Journal:  Eur J Clin Pharmacol       Date:  2014-08-23       Impact factor: 2.953

Review 9.  The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?

Authors:  Marco Vitoria; Andrew Hill; Nathan Ford; Meg Doherty; Polly Clayden; Francois Venter; David Ripin; Charles Flexner; Paul L Domanico
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.